Search Results - therapeutics+%3e+oncology

130 Results

Sort By:

Fish Oil Plus Diet for Prostate Health (UCLA Case No. 2024-092)

UCLA researchers from the Department of Urology have identified a dietary intervention that may slow prostate cancer progression, offering a promising accessible, safe, and non-invasive approach to managing prostate health. BACKGROUND: Prostate cancer is the second most commonly diagnosed cancer in the United States and the fifth leading cause of death...

Published: 6/20/2025 | Inventor(s): William Aronson

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Metabolism And Endocrinology

Reverse Engineering Vaccine Antigens (UCLA Case No. 2025-074)

UCLA researchers from the Department of Pediatrics-Allergy/Immunology have developed a novel platform to reverse engineer vaccine antigens for the prevention and treatment of infectious disease and cancer. BACKGROUND: Vaccines function by introducing antigens into a host to stimulate an immune response, providing protection against pathogens and certain...

Published: 6/19/2025 | Inventor(s): Manish Butte

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Infectious Diseases, Therapeutics > Vaccines

Modified Hyaluronic Acid Hydrogels Containing Hyaluronidase for the Time‐Controlled and Targeted Release of anti-CTLA-4 and other Therapeutic Antibodies (UCLA Case No. 2016-526)

UCLA researchers from the Department of Medicine have developed a novel therapeutic platform for the administration of low-dose Cytotoxic T-lymphocyte Associated Protein 4 (CTLA-4) antibody for cancer immunotherapy that synergizes with conventional PD-1 therapy while sparing systemic autoimmune toxicity. BACKGROUND: Immune checkpoint inhibitor (CPI)...

Published: 5/30/2025 | Inventor(s): Michael Roth, Airi Harui

Keywords(s): Cancer Immunotherapy, Immunotherapy

Category(s): Platforms > Drug Delivery, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology

Analoging and SAR-Based Chemical Approach to Improve the Therapeutic Potency of Small-Molecule Inhibitors of Metastasis (UCLA Case No. 2024-116)

UCLA researchers in the Department of Molecular and Medical Pharmacology have developed an analoging and SAR-based chemical approach to generate novel, safe, and effective small-molecule inhibitors for preventing and treating cancer metastasis. BACKGROUND: The limited understanding of the biological mechanisms underlying metastasis in clear cell renal...

Published: 5/14/2025 | Inventor(s): Lily Wu, Moe Ishihara, Robert Damoiseaux, Stuart Conway

Keywords(s): Cancer, Metastasis, Oncology (Small Molecules, Peptides and Antibodies), Small molecule therapeutics, small molecules

Category(s): Therapeutics > Oncology

KHK Inhibitors as Agents for the Treatment of Cancer and Metabolic Syndrome (UCLA Case No. 2021-222)

UCLA researchers in the Department of Chemistry and Biochemistry have synthesized novel KHK inhibitors that can result in anticancer drugs targeting cancer metabolism. BACKGROUND: Fructose is a naturally occurring sugar found in fruits and vegetables, and is an integral part of the human diet. In comparison to its functional isomer, glucose, which...

Published: 3/31/2025 | Inventor(s): Heather Christofk, Michael Jung

Keywords(s): Cancer, cancer metabolism, metabolism, Oncology (Small Molecules, Peptides and Antibodies), small molecules

Category(s): Therapeutics > Oncology, Therapeutics > Metabolism And Endocrinology

Novel Strategy to Produce Bi-specific Chimeric Antigen Receptors (UCLA Case No. 2024-169)

Researchers in the Department of Medicine and the Department of Microbiology, Immunology and Molecular Genetics have created novel bi-specific chimeric antigen receptors. BACKGROUND: Chimeric antigen receptors (CARs) are synthetic receptors engineered to redirect T cells towards specific targets on other cells, typically using a single chain antibody....

Published: 2/14/2025 | Inventor(s): Otto Yang

Keywords(s):

Category(s): Therapeutics > Oncology

Small Molecules that Inhibit RNA Binding Protein IGF2BP3 in Cancer (UCLA Case No. 2023-215)

UCLA researchers in the Department of Pathology and Laboratory Medicine have developed small molecules which inhibits the protein IGF2BP3, a highly expressed oncofetal protein in certain cancers, especially in B-acute lymphoblastic leukemia. BACKGROUND: Cancer remains the second leading cause of death in the U.S. Advancements in targeted therapies...

Published: 2/14/2025 | Inventor(s): Dinesh Rao

Keywords(s): blood cancers, Cancer, cancer inhibition, leukemia

Category(s): Therapeutics > Oncology

Methods To Predict the Efficacy of Neoadjuvant Anti-PD-1 Therapy in Resectable Oral-Cavity Squamous Cell Carcinoma and Target Post-Surgical Relapses (UCLA Case No. 2022-039)

UCLA researchers in the School of Medicine have developed a novel therapeutic strategy to improve prognosis of resectable head and neck cancer patients based on clinical studies. BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is an aggressive and recurrent cancer, ranked sixth among common epithelial malignancies worldwide. Over a third...

Published: 2/14/2025 | Inventor(s): Roger Lo

Keywords(s): anti-PD-1, head and neck cancer, head and neck squamous cell carcinoma (HNSCC), Immunotherapy, oral cavity squamous cell carcinoma (OCSCC), resectable tumors

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

Combination Cancer Therapy Methods and Agents (UCLA Case No. 2024-084)

UCLA researchers from the Department of Medicine, Pathology, & Laboratory Medicine and Molecular & Medical Pharmacology have identified a novel cell-based therapy that leads to enhanced immunotherapy efficacy and overcomes treatment resistance to immune checkpoint blockade in non-small cell lung cancer. BACKGROUND: Non-small cell lung cancer...

Published: 2/14/2025 | Inventor(s): Bin Liu, Steven Dubinett

Keywords(s): anti-tumor immunity, cell-based therapy, Immune checkpoint blockade, Immunotherapy, non-small cell lung cancer, treatment resistance, Tumor microenvironment, Vaccines

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Respiratory And Pulmonary

Interferon Activation Score Is a Biomarker for Immunotherapy in Malignant Glioma Patients (UCLA Case No. 2024-043)

UCLA researchers from the Department of Neurosurgery have characterized immune responses in malignant glioma patients receiving immunotherapy to develop a robust biomarker that will allow prediction of clinical outcomes following treatment. BACKGROUND: Malignant gliomas are the most common primary brain tumors in adults. No cures exist and most gliomas...

Published: 2/14/2025 | Inventor(s): Robert Prins

Keywords(s): adjuvant therapy, Biomarker, Chemotherapy, Clinical Trial, dendritic cell vaccination, Glioblastoma, Glioma, immune response, Immunotherapy, interferon, malignant glioma

Category(s): Diagnostic Markers > Immunology, Diagnostic Markers > Cancer, Therapeutics > Inflammation And Inflammatory Diseases, Therapeutics > Oncology, Therapeutics > CNS and Neurology

1 2 3 4 5 6 7 8 9 10 ...